Home Cart Sign in  
Chemical Structure| 1370347-50-4 Chemical Structure| 1370347-50-4

Structure of 1370347-50-4

Chemical Structure| 1370347-50-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1370347-50-4 ]

CAS No. :1370347-50-4
Formula : C7H7Cl2NO
M.W : 192.04
SMILES Code : C[C@H](O)C1=C(Cl)C=NC=C1Cl
MDL No. :MFCD22665797
InChI Key :KCPDCYCCMCEYQN-BYPYZUCNSA-N
Pubchem ID :66831621

Safety of [ 1370347-50-4 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 1370347-50-4 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 6
Fraction Csp3 0.29
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 45.19
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

33.12 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.94
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.62
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.12
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.4
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.61
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.94

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.39
Solubility 0.784 mg/ml ; 0.00408 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.93
Solubility 2.27 mg/ml ; 0.0118 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.12
Solubility 0.145 mg/ml ; 0.000757 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.32 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.99

Application In Synthesis of [ 1370347-50-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1370347-50-4 ]
  • Downstream synthetic route of [ 1370347-50-4 ]

[ 1370347-50-4 ] Synthesis Path-Upstream   1~3

  • 1
  • [ 1254473-66-9 ]
  • [ 1370347-50-4 ]
YieldReaction ConditionsOperation in experiment
27% With CHIRALPAK.(R). AD-H column In ethanol; n-heptaneResolution of racemate S)- 1 -(3,5-Dichloropyridin-4-yl)ethanol Separate the mixture of stereoisomers obtained in the above reaction on a CHIRALPAK.(R). AD-H column eluting with 90percent heptanes/ 10percent ethanol. Peak 2 is the desired enantiomer. To establish the absolute configuration dissolve a sample of the product in CDCI3 (final concentration 100 mg/mL). Obtain the vibrational circular dichroism (VCD) and infra red (IR) spectra with a resolution of 4 cm- 1 using a ChiralIR FT VCD spectrometer (BioTools Inc .(R).) with an IR cell equipped with BaF2 windows and a path length of 100 mm. Collect the VCD and IR for 6 hours with 150 μL of the sample. Present the data without smoothing or further data processing. Obtain vibrational frequencies and absorption and VCD intensities by optimizing the lowest energy conformer by Gaussian at the B3PW91/6-3 IG** level on a Linux cluster, and simulate the corresponding spectra using a Lorentzian bandwidth of 6 cm- 1 vibrational circular dichroism. The above analysis shows the product to be the S- isomer. Yield: 84.37 g (27percent). MS (ES) m/z 192 [MH-I]+.
27% With CHIRALPAK AD-H column In ethanol; n-heptaneResolution of racemate Separate the mixture of stereoisomers obtained in Preparation 1 on a CHIRALPAK.(R). AD-H column eluting with 90percent heptanes/10percent ethanol. Peak 2 is the desired enantiomer. To establish the absolute configuration dissolve a sample of the product in CDCl3 (final concentration 100 mg/mL). Obtain the vibrational circular dichroism (VCD) and infra red (IR) spectra with a resolution of 4 cm-1 using a ChiralIR FT VCD spectrometer (BioTools Inc.(R).) with an IR cell equipped with BaF2 windows and a path length of 100 mm. Collect the VCD and IR for 6 hours with 150 μL of the sample. Present the data without smoothing or further data processing. Obtain vibrational frequencies and absorption and VCD intensities by optimizing the lowest energy conformer by Gaussian at the B3PW91/6-31G** level on a Linux cluster, and simulate the corresponding spectra using a Lorentzian bandwidth of 6 cm-1 vibrational circular dichroism. The above analysis shows the product to be the S-isomer. Yield: 84.37 g (27percent). MS (ES) m/z 192 [M+1]+.
References: [1] Patent: WO2010/129509, 2010, A1, . Location in patent: Page/Page column 4.
[2] Patent: US2012/83511, 2012, A1, . Location in patent: Page/Page column 2.
[3] Journal of Medicinal Chemistry, 2016, vol. 59, # 14, p. 6690 - 6708.
[4] Journal of Medicinal Chemistry, 2016, vol. 59, # 14, p. 6690 - 6708.
[5] Patent: CN103819396, 2016, B, .
[6] Patent: EP3333157, 2018, A1, .
  • 2
  • [ 2457-47-8 ]
  • [ 1370347-50-4 ]
References: [1] Patent: US2012/83511, 2012, A1, .
[2] Journal of Medicinal Chemistry, 2016, vol. 59, # 14, p. 6690 - 6708.
[3] Journal of Medicinal Chemistry, 2016, vol. 59, # 14, p. 6690 - 6708.
[4] Patent: CN103819396, 2016, B, .
[5] Patent: EP3333157, 2018, A1, .
  • 3
  • [ 1370347-50-4 ]
  • [ 1254473-64-7 ]
References: [1] Patent: US2012/83511, 2012, A1, .
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 1370347-50-4 ]

Chlorides

Chemical Structure| 1254473-66-9

A200126 [1254473-66-9]

1-(3,5-Dichloropyridin-4-yl)ethanol

Similarity: 1.00

Chemical Structure| 100868-46-0

A190792 [100868-46-0]

3,5-Dichloro-4-methylpyridine

Similarity: 0.75

Chemical Structure| 13958-93-5

A154264 [13958-93-5]

3,5-Dichloroisonicotinic acid

Similarity: 0.73

Chemical Structure| 406676-18-4

A257719 [406676-18-4]

2,3,5-Trichloroisonicotinic acid

Similarity: 0.70

Chemical Structure| 275383-87-4

A125055 [275383-87-4]

(3,5-Dichloropyridin-2-yl)methanol

Similarity: 0.69

Alcohols

Chemical Structure| 1254473-66-9

A200126 [1254473-66-9]

1-(3,5-Dichloropyridin-4-yl)ethanol

Similarity: 1.00

Chemical Structure| 275383-87-4

A125055 [275383-87-4]

(3,5-Dichloropyridin-2-yl)methanol

Similarity: 0.69

Chemical Structure| 886364-92-7

A135906 [886364-92-7]

5-Chloro-4-methylpyridin-2-ol

Similarity: 0.65

Chemical Structure| 1956389-98-2

A281783 [1956389-98-2]

2-Amino-2-(3-chloropyridin-4-yl)ethanol hydrochloride

Similarity: 0.64

Chemical Structure| 27652-89-7

A143082 [27652-89-7]

(4-Chlorophenyl)(pyridin-2-yl)methanol

Similarity: 0.64

Related Parent Nucleus of
[ 1370347-50-4 ]

Pyridines

Chemical Structure| 1254473-66-9

A200126 [1254473-66-9]

1-(3,5-Dichloropyridin-4-yl)ethanol

Similarity: 1.00

Chemical Structure| 100868-46-0

A190792 [100868-46-0]

3,5-Dichloro-4-methylpyridine

Similarity: 0.75

Chemical Structure| 13958-93-5

A154264 [13958-93-5]

3,5-Dichloroisonicotinic acid

Similarity: 0.73

Chemical Structure| 406676-18-4

A257719 [406676-18-4]

2,3,5-Trichloroisonicotinic acid

Similarity: 0.70

Chemical Structure| 275383-87-4

A125055 [275383-87-4]

(3,5-Dichloropyridin-2-yl)methanol

Similarity: 0.69